Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
13.1M
-
Number of holders
-
147
-
Total 13F shares, excl. options
-
16.5M
-
Shares change
-
-773K
-
Total reported value, excl. options
-
$1.31B
-
Value change
-
-$54.4M
-
Put/Call ratio
-
0.89
-
Number of buys
-
75
-
Number of sells
-
-59
-
Price
-
$79.34
Significant Holders of EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX) as of Q4 2016
175 filings reported holding EGRX - EAGLE PHARMACEUTICALS, INC. - Common Stock as of Q4 2016.
EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX) has 147 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.5M shares
.
Largest 10 shareholders include ProQuest Associates IV LLC (3.95M shares), JANUS CAPITAL MANAGEMENT LLC (1.48M shares), Hudson Executive Capital LP (951K shares), VICTORY CAPITAL MANAGEMENT INC (863K shares), BlackRock Fund Advisors (853K shares), ORBIMED ADVISORS LLC (671K shares), STATE STREET CORP (654K shares), First Eagle Investment Management, LLC (635K shares), Park West Asset Management LLC (580K shares), and JW Asset Management, LLC (526K shares).
This table shows the top 147 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.